Immunome Inc.

IMNM Nasdaq SEC CIK 1472012
Follow Immunome Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$85.8M −49.3% vs same quarter last year
EPS, diluted −$0.76 −16.9% vs same quarter last year
Operating cash flow −$60.8M −50% vs same quarter last year
Revenue by quarter
$2.7M
$2.9M
$4M
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$6.9M−$212.4M
FY24$9M−$293M
FY23$14M−$106.8M
FY22-−$36.9M
FY21-−$24.7M
FY20-−$17.8M
FY19-−$10.4M
FY18--
MarginsShare of revenue
  • Operating margin
  • Net margin
−4000%−3000%−2000%−1000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−3228.8%−3060%
FY24−3382.4%−3240.4%
FY23−781.4%−761.9%
FY22--
FY21--
FY20--
FY19--
FY18--
Free cash flowOperating cash flow minus capital expenditure
−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$200.6M
FY24−$118M
FY23−$8.4M
FY22−$28.9M
FY21−$18.3M
FY20−$12.7M
FY19−$9.8M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Immunome
  • Healthcare median
−4000%−3000%−2000%−1000%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearImmunomeHealthcare median
FY25−3060%−30.6%
FY24−3240.4%−47%
FY23−761.9%−58%
FY22-−80.4%
FY21-−71.9%
FY20-−62.2%
FY19-−46.3%
FY18-−49.6%